Melanoma: BRAF Status and a Neoadjuvant Therapy Approach

Source: OncLive, August 2019

Sanjiv S. Agarwala, MD: Hello, and thank you for joining this OncLive Peer Exchange® titled “Expert Perspectives on the Treatment of Melanoma.” We have made enormous strides in developing novel therapies for advanced melanoma, particularly in the field of immuno-oncology, where melanoma has been at the forefront of paradigm-defining progress. We continue to see new advances at an accelerated pace as we learn more about the disease itself and how to treat it.

Today I’m joined by a group of international experts in the field of melanoma research. Together we will discuss the studies presented at the 2019 ASCO [American Society of Clinical Oncology] Annual Meeting and will provide you with perspective on how the data relate to clinical practice.

I am Dr Sanjiv Agarwala, a professor of medicine at Lewis Katz School of Medicine at Temple University in Philadelphia, Pennsylvania, and the chief of oncology and hematology at St. Luke’s University Health Network in Bethlehem, Pennsylvania.